CRNX | Ticker Profile - Titan Protect

CRNX

Crinetics Pharmaceuticals, Inc.

Healthcare · Biotechnology · NMS

$32.92

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.74

Based on estimated future earnings — lower means cheaper

Rev Growth

+2,873.4%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-39.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$86.00

+161% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 14 analysts covering this stock

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

https://www.crinetics.com

Country: United States Employees: 594 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.041

Positive but modest risk-adjusted returns

Kelly Fraction

0.0017

Marginal edge — very small allocation suggested

Calmar Ratio

-0.197

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-11.4%

Historical annualised return based on price data

Max Drawdown

-57.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.28

Very low correlation to market moves

52W High

$57.99

43% below the year high

52W Low

$25.83

27% above the year low

Avg Volume

1,205,544

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

14.6%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.74

Heavy leverage — higher financial risk if revenues decline

Current Ratio

18.60

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

18.25

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,307.8%

Profit from core operations before interest and tax

Free Cash Flow

$-242,135,744

Negative — the business is spending more than it generates

Revenue (TTM)

$18M

Total revenue over the last 12 months

Net Income

$-496,388,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$97.00

Target Median

$86.00

Target Low

$55.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go